Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Lung Neoplasms 4Sezary Syndrome 3Mycosis Fungoides 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large B-Cell, Diffuse 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Rectal Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Melanoma 1Lymphoma, T-Cell 1Gliosarcoma 1Glioma 1Glioblastoma 1Extensive Stage Lung Small Cell Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Colitis 1Cholangiocarcinoma 1Cervical Adenocarcinoma 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 69Radiotherapy 30Bevacizumab 24Carboplatin 13pembrolizumab 12Radiation 11Carmustine 8Irinotecan 7temsirolimus 6Surgical Procedures, Operative 6Radiosurgery 6Erlotinib Hydrochloride 6atezolizumab 5Vorinostat 5Sirolimus 5Radiotherapy, Intensity-Modulated 5Nivolumab 5Lomustine 5Everolimus 5fludarabine 4Radiotherapy, Conformal 4Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Aminolevulinic Acid 4tipifarnib 3Sorafenib 3Paclitaxel 3IL13-PE38 3Granulocyte-Macrophage Colony-Stimulating Factor 3Gemcitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Glioblastoma × Disulfides × Clear all
NCT01648348 2018-05-23

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 1/2 Completed
116 enrolled 17 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡